Key result
Testing for genetic variants in vitamin K epoxide reductase and cytochrome P450 prior to anticoagulation therapy may help prevent severe adverse drug reactions or avoid therapeutic failure.
Why the study?
Does pharmacogenetic testing for vitamin K epoxide reductase and cytochrome P450 variants prevent adverse drug reactions or therapeutic failure in patients receiving anticoagulation?
Does pharmacogenetic testing for vitamin K epoxide reductase and cytochrome P450 variants prevent adverse drug reactions or therapeutic failure in patients receiving anticoagulation?
Pharmacogenetic testing for variants in vitamin K epoxide reductase and cytochrome P450 may help prevent adverse drug reactions and therapeutic failure in patients receiving anticoagulants.
Answers are grounded in this paper and cite their sources.
Should not yet change anticoagulation practice; leaves open confirmation of benefit in prospective RCTs.
Advances in the field of human genetics has made it possible to develop prevention strategies for rare genetic disorders and to tailor pharmacotherapeutic approaches to anticoagulation and certain cancers. However, it is still not clear how genetic variations influence the risk and outcome of common diseases. Data from genome-wide association studies is just beginning to answer these questions. In contrast, pharmacogenetic knowledge is frequently not yet translated into clinical practice, even though in some cases, particularly regarding drugs used in treatment of thrombotic diseases (e.g., coumarines, platelet aggregation inhibitors), it is already known that testing for genetic variants prior to pharmacotherapy may help to prevent severe adverse drug reactions or avoid therapeutic failure. In this review, we address the potential impact that genetic alterations in the genes for vitamin K epoxide reductase and some cytochrome P450 variants may have on therapeutic strategies in anticoagulation.
No takes yet. Share an insight, caveat, or question.
Sunder‐Plaßmann et al. (2010) conducted a review in Thrombotic diseases requiring anticoagulation. Pharmacogenetics guided anticoagulation was evaluated. Testing for genetic variants in vitamin K epoxide reductase and cytochrome P450 prior to anticoagulation therapy may help prevent severe adverse drug reactions or avoid therapeutic failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: